ANI Pharmaceuticals (NASDAQ:ANIP): Q2 Non-GAAP EPS of $1.44 beats by $0.16; GAAP EPS of $0.53 beats by $0.01.
Revenue of $54.36M (+15.0% Y/Y) misses by $0.84M.
Wednesday, August 7, 2019
Premarket analyst action, Aug. 7
Neurocrine Biosciences (NASDAQ:NBIX) initiated with Outperform rating and $118 (24% upside) price target at RBC.
MediPharm Labs (LABS CN) initiated with Buy rating and C$9 (53% upside) price target at ROTH Capital.
Regeneron Pharmaceuticals (NASDAQ:REGN) upgraded to Outperform with a $410 (37% upside) price target at Baird.
Allergan (NYSE:AGN) downgraded to Neutral at Guggenheim.
AxoGen (NASDAQ:AXGN) downgraded to Market Perform at William Blair. Shares down 8% premarket after its Q2 revenue miss and guidance cut.
Xencor (NASDAQ:XNCR) downgraded to Market Perform at Raymond James and Neutral at Guggenheim after it released Q2 results yesterday after the close.
Horizon Pharma EPS beats by $0.12, beats on revenue
Horizon Pharma (NASDAQ:HZNP): Q2 Non-GAAP EPS of $0.49 beats by $0.12; GAAP EPS of -$0.03.
Revenue of $320.6M (+5.9% Y/Y) beats by $24.33M.
ArQule EPS beats by $0.01, misses on revenue
ArQule (NASDAQ:ARQL): Q2 GAAP EPS of -$0.08 beats by $0.01.
Revenue of $0.28M (-98.0% Y/Y) misses by $0.61M.
AMAG Pharmaceuticals EPS of -$3.57
AMAG Pharmaceuticals (NASDAQ:AMAG): Q2 EPS of -$3.57 may not be comparable to consensus of -$0.88.
Revenue of $78.11M (-46.6% Y/Y) misses by $12.61M.
Ionis Pharmaceuticals EPS beats by $0.26, beats on revenue
Ionis Pharmaceuticals (NASDAQ:IONS): Q2 GAAP EPS of -$0.01 beats by $0.26.
Revenue of $164M (+39.0% Y/Y) beats by $18.69M.
Intercept Pharma EPS beats by $0.33, beats on revenue
Intercept Pharma (NASDAQ:ICPT): Q2 GAAP EPS of -$2.28 beats by $0.33.
Revenue of $66.3M (+52.1% Y/Y) beats by $7.52M.
Subscribe to:
Posts (Atom)